New hope for steroid users: drug may shield stomach from damage
NCT ID NCT05946135
First seen Jan 14, 2026 · Last updated May 07, 2026 · Updated 15 times
Summary
This study tested whether fexuprazan, a new stomach acid reducer, can prevent or control gastritis (stomach inflammation) symptoms in people who need to take systemic steroids for at least 4 weeks. 42 adults with respiratory diseases were randomly assigned to take either fexuprazan or the standard drug lansoprazole for 4 weeks. The main goal was to see if fexuprazan better reduced gastritis symptoms compared to the standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS ON TREATMENT WITH SYSTEMIC STEROIDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.